0001104659-22-070182.txt : 20220610 0001104659-22-070182.hdr.sgml : 20220610 20220610164838 ACCESSION NUMBER: 0001104659-22-070182 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220609 FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carson Sandra CENTRAL INDEX KEY: 0001813742 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36464 FILM NUMBER: 221009570 MAIL ADDRESS: STREET 1: C/O AGILE THERAPEUTICS, INC. STREET 2: 101 POOR FARM ROAD CITY: PRINCETON STATE: NJ ZIP: 08540 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC CENTRAL INDEX KEY: 0001261249 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 COLLEGE ROAD EAST STREET 2: SUITE 310 CITY: PRINCETON STATE: NJ ZIP: 08540-6635 BUSINESS PHONE: 609-683-1880 MAIL ADDRESS: STREET 1: 500 COLLEGE ROAD EAST STREET 2: SUITE 310 CITY: PRINCETON STATE: NJ ZIP: 08540-6635 4 1 tm2218213-6_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-06-09 0 0001261249 AGILE THERAPEUTICS INC AGRX 0001813742 Carson Sandra 500 COLLEGE ROAD EAST, SUITE 310 PRINCETON NJ 08540 1 0 0 0 Common Stock 2022-06-09 4 A 0 670 0 A 1952 D Employee Stock Option (Right to Buy) 1.22 2022-06-09 4 A 0 807 0 A 2032-06-08 Common Stock 807 807 D These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split. This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service. /s/ Geoffrey P. Gilmore, Attorney-in-fact 2022-06-10